Legal Representation
Attorney
Nicole Kinsley, Esq.
USPTO Deadlines
Next Deadline
119 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
November 26, 2025
Extension Available
Until November 26, 2025
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 11, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 10, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 10, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Mar 10, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 26, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 1, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 1, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 11, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 26, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 18, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 18, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 18, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 24, 2024 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Apr 24, 2024 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Feb 7, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 7, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 7, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 26, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 30, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 4, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceuticals for the treatment of neurodegenerative disorders, amyotrophic lateral sclerosis (ALS), dementia, cancer, Parkinson's Disease, and obesity; pharmaceuticals for the treatment of life-threatening diseases; pharmaceuticals, namely, ribonucleic acid (RNA) therapeutics; pharmaceuticals, namely, ribonucleic acid (RNA) therapeutics for use in the treatment of neurodegenerative disorders, amyotrophic lateral sclerosis (ALS), dementia, cancer, Parkinson's Disease, and obesity; pharmaceuticals, namely, ribonucleic acid (RNA) therapeutics that feature RNA as their active ingredient; pharmaceuticals, namely, small molecule therapeutics that induce changes in the chemical modifications of ribonucleic acid (RNA)
Additional Information
Translation
The wording TINOS has no meaning in a foreign language.
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"